| Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial S Loi, S Michiels, R Salgado, N Sirtaine, V Jose, D Fumagalli, ... Annals of oncology 25 (8), 1544-1550, 2014 | 1360 | 2014 |
| Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer ANJ Tutt, JE Garber, B Kaufman, G Viale, D Fumagalli, P Rastogi, ... New England Journal of Medicine 384 (25), 2394-2405, 2021 | 936 | 2021 |
| Luminal B breast cancer: molecular characterization, clinical management, and future perspectives F Ades, D Zardavas, I Bozovic-Spasojevic, L Pugliano, D Fumagalli, ... Journal of clinical oncology 32 (25), 2794-2803, 2014 | 455 | 2014 |
| Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial S Loi, A Giobbie-Hurder, A Gombos, T Bachelot, R Hui, G Curigliano, ... The Lancet Oncology 20 (3), 371-382, 2019 | 390 | 2019 |
| Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value PG Gavin, LH Colangelo, D Fumagalli, N Tanaka, MY Remillard, ... Clinical cancer research 18 (23), 6531-6541, 2012 | 341 | 2012 |
| Genomic characterization of primary invasive lobular breast cancer C Desmedt, G Zoppoli, G Gundem, G Pruneri, D Larsimont, M Fornili, ... Journal of clinical oncology 34 (16), 1872-1881, 2016 | 304 | 2016 |
| Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer F Rothé, JF Laes, D Lambrechts, D Smeets, D Vincent, M Maetens, ... Annals of oncology 25 (10), 1959-1965, 2014 | 272 | 2014 |
| PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2–targeted therapies in breast cancer IJ Majewski, P Nuciforo, L Mittempergher, AJ Bosma, H Eidtmann, ... Journal of Clinical Oncology 33 (12), 1334, 2015 | 252 | 2015 |
| 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age M Piccart, LJ van't Veer, C Poncet, JMNL Cardozo, S Delaloge, JY Pierga, ... The Lancet Oncology 22 (4), 476-488, 2021 | 231 | 2021 |
| Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer in the APHINITY trial: 6 years' follow-up M Piccart, M Procter, D Fumagalli, E de Azambuja, E Clark, MS Ewer, ... Journal of Clinical Oncology 39 (13), 1448-1457, 2021 | 230 | 2021 |
| Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study EL Mayer, AC Dueck, M Martin, G Rubovszky, HJ Burstein, ... The lancet oncology 22 (2), 212-222, 2021 | 226 | 2021 |
| Principles governing A-to-I RNA editing in the breast cancer transcriptome D Fumagalli, D Gacquer, F Rothé, A Lefort, F Libert, D Brown, ... Cell reports 13 (2), 277-289, 2015 | 204 | 2015 |
| Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer S Loi, S Michiels, D Lambrechts, D Fumagalli, B Claes, ... Journal of the National Cancer Institute 105 (13), 960-967, 2013 | 148 | 2013 |
| A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes D Fumagalli, PG Gavin, Y Taniyama, SI Kim, HJ Choi, S Paik, ... BMC cancer 10, 1-14, 2010 | 145 | 2010 |
| Impact of diabetes, insulin, and metformin use on the outcome of patients with human epidermal growth factor receptor 2–positive primary breast cancer: analysis from the ALTTO … A Sonnenblick, D Agbor-Tarh, I Bradbury, S Di Cosimo, HA Azim Jr, ... Journal of Clinical Oncology 35 (13), 1421, 2017 | 142 | 2017 |
| Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor–positive breast cancer C Kim, G Tang, KL Pogue-Geile, JP Costantino, FL Baehner, J Baker, ... Journal of clinical oncology 29 (31), 4160, 2011 | 138 | 2011 |
| RNA sequencing to predict response to neoadjuvant anti-HER2 therapy: a secondary analysis of the NeoALTTO randomized clinical trial D Fumagalli, D Venet, M Ignatiadis, HA Azim, M Maetens, F Rothé, ... JAMA oncology 3 (2), 227-234, 2017 | 136 | 2017 |
| Molecular profiling: moving away from tumor philately JS Reis-Filho, B Weigelt, D Fumagalli, C Sotiriou Science translational medicine 2 (47), 47ps43-47ps43, 2010 | 125 | 2010 |
| The prognostic role of androgen receptor in patients with early-stage breast cancer: a meta-analysis of clinical and gene expression data I Bozovic-Spasojevic, D Zardavas, S Brohée, L Ameye, D Fumagalli, ... Clinical Cancer Research 23 (11), 2702-2712, 2017 | 124 | 2017 |
| Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31 KL Pogue-Geile, C Kim, JH Jeong, N Tanaka, H Bandos, PG Gavin, ... Journal of the National Cancer Institute 105 (23), 1782-1788, 2013 | 121 | 2013 |
Stefan MichielsOffice Biostatistics & Epidemiology, Gustave Roussy; Oncostat, Univ. Paris Saclay, INSERMVerified email at gustaveroussy.fr
